Nicorandil as a novel therapy for advanced diabetic nephropathy in the eNOS-deficient mouse.
about
Diabetic Kidney Disease: Pathophysiology and Therapeutic TargetsUric acid-dependent inhibition of AMP kinase induces hepatic glucose production in diabetes and starvation: evolutionary implications of the uricase loss in hominidsRole of endothelial nitric oxide synthase in diabetic nephropathy: lessons from diabetic eNOS knockout miceEndogenous fructose production and fructokinase activation mediate renal injury in diabetic nephropathy.Role of the KATP channel in the protective effect of nicorandil on cyclophosphamide-induced lung and testicular toxicity in ratsSubcellular trafficking of guanylyl cyclase/natriuretic peptide receptor-A with concurrent generation of intracellular cGMPRole of FQQI motif in the internalization, trafficking, and signaling of guanylyl-cyclase/natriuretic peptide receptor-A in cultured murine mesangial cellsNicorandil attenuates carotid intimal hyperplasia after balloon catheter injury in diabetic rats.Epicatechin limits renal injury by mitochondrial protection in cisplatin nephropathy.Protective role of fructokinase blockade in the pathogenesis of acute kidney injury in mice.Uncoupling of VEGF with endothelial NO as a potential mechanism for abnormal angiogenesis in the diabetic nephropathy.Combination of ACE inhibitor with nicorandil provides further protection in chronic kidney disease.Antiangiogenic Therapy for Diabetic Nephropathy.Aging-associated renal disease in mice is fructokinase dependent.Nicorandil ameliorated hypertensive renal injury without lowering blood pressure in spontaneously hypertensive rats.Deletion of pro-angiogenic factor vasohibin-2 ameliorates glomerular alterations in a mouse diabetic nephropathy model.
P2860
Q28086840-08804C25-7C0B-47A3-94EF-6E5AAC303021Q33913203-326FEAB9-5CC9-40E7-8FB0-440303495D92Q34412951-DD3E06E3-3398-42C6-B77D-75218A47B795Q34427632-81F22666-8C7A-497D-AF15-FFF8635962C3Q36099894-495C3655-FF34-4C46-AC99-E93537526D08Q36227341-372CCBC1-8E1E-4DF5-B797-0E2F378A5778Q36363355-5230EEF1-3F40-4AEB-9B3D-419A15F2279DQ36783324-FEE912FF-62D6-4927-B677-6BFD50D603B1Q37592492-8EC9FBBA-0F4F-413F-90F7-AB34C4CFFD69Q37651822-71351D68-4690-442C-95E9-F71400EFD14DQ38175408-BEB6FCD9-3C6F-4322-9795-9815AC88AEE0Q38947325-DF6461BD-A99A-4281-99EF-5E3C87C90ACDQ41403094-D72D503D-AD34-4196-994E-6A194BA02C6BQ41630792-31D19B8C-C4D1-429E-85E5-DE4AF8C5D670Q44468524-87208AAD-1DE1-4D0F-BBD8-EED6C0ECA0ECQ52594144-D83CB2E9-4E88-4631-B01A-F7F176E2D286
P2860
Nicorandil as a novel therapy for advanced diabetic nephropathy in the eNOS-deficient mouse.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Nicorandil as a novel therapy ...... y in the eNOS-deficient mouse.
@ast
Nicorandil as a novel therapy ...... y in the eNOS-deficient mouse.
@en
type
label
Nicorandil as a novel therapy ...... y in the eNOS-deficient mouse.
@ast
Nicorandil as a novel therapy ...... y in the eNOS-deficient mouse.
@en
prefLabel
Nicorandil as a novel therapy ...... y in the eNOS-deficient mouse.
@ast
Nicorandil as a novel therapy ...... y in the eNOS-deficient mouse.
@en
P2093
P2860
P1476
Nicorandil as a novel therapy ...... y in the eNOS-deficient mouse.
@en
P2093
Christopher J Rivard
George F Schreiner
Hirofumi Makino
Jelena Klawitter
Katsuyuki Tanabe
Makoto Miyazaki
Miguel A Lanaspa
Moin A Saleem
Peter W Mathieson
Richard J Johnson
P2860
P304
P356
10.1152/AJPRENAL.00596.2011
P577
2012-02-15T00:00:00Z